Cited by 888Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record.

Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Ross, R. K.·2000·Journal of the National Cancer Institute

Open this paper in CoChat — free account

Abstract

BACKGROUND: Hormone replacement therapy (HRT) given as unopposed estrogen replacement therapy (ERT) gained widespread popularity in the United States in the 1960s and 1970s. Recent prescribing practices have favored combination HRT (CHRT), i.e., adding a progestin to estrogen for the entire monthly cycle (continuous combined replacement therapy [CCRT]) or a part of the cycle (sequential estrogen plus progestin therapy [SEPRT]). Few data exist on the association between CHRT and breast cancer risk. We determined the effects of CHRT on a woman's risk of developing breast cancer in a population-based, case-control study. METHODS: Case subjects included those with incident breast cancers diagnosed over 4(1/2) years in Los Angeles County, CA, in the late 1980s and 1990s. Control subjects were neighborhood residents who were individually matched to case subjects on age and race. Case subjects and control subjects were interviewed in person to collect information on known breast cancer risk factors as well as on HRT use. Information on 1897 postmenopausal case subjects and on 1637 postmenopausal control subjects aged 55-72 years who had not undergone a simple hysterectomy was analyzed. Breast cancer risks associated with the various types of HRT were estimated as odds ratios (ORs) after adjusting simultaneously for the different forms of HRT and for known risk factors of breast cancer. All P values are two-sided. RESULTS: HRT was associated with a 10% higher breast cancer risk for each 5 years of use (OR(5) = 1.10; 95% confidence interval [CI] = 1.02-1.18). Risk was substantially higher for CHRT use (OR(5) = 1.24; 95% CI = 1.07-1.45) than for ERT use (OR(5) = 1. 06; 95% CI = 0.97-1.15). Risk estimates were higher for SEPRT (OR(5) = 1.38; 95% CI = 1.13-1.68) than for CCRT (OR(5) = 1.09; 95% CI = 0. 88-1.35), but this difference was not statistically significant. CONCLUSIONS: This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone. These findings have important implications for the risk-benefit equation for HRT in women using CHRT.

Integrity signals

Registry

Crossref · 10.1093/jnci/92.4.328

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 201–300 of 888

Body size, hormone therapy and risk of breast cancer in Asian–American women
Wu, A. H., Yu, M. C., Tseng, C., & Pike, M. C. (2006) · International Journal of Cancer · doi:10.1002/ijc.22387 · Cited by 65
Menopausal Hormone Therapy and Subsequent Risk of Specific Invasive Breast Cancer Subtypes in the California Teachers Study
Saxena, T., Lee, E., Henderson, K. D., Clarke, C. A., West, D. W., Marshall, S. F., Deapen, D., Bernstein, L., & Ursin, G. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0162 · Cited by 63
Progestin Effects on Long-Term Growth, Death, and Bcl-xL in Breast Cancer Cells
Moore, M. R., Conover, J. L., & Franks, K. M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3728 · Cited by 63
Progestin-Dependent Induction of Vascular Endothelial Growth Factor in Human Breast Cancer Cells
Wu, J., Richer, J. K., Horwitz, K. B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3044 · Cited by 63
Chemotherapeutic effects of Apigenin in breast cancer: Preclinical evidence and molecular mechanisms; enhanced bioavailability by nanoparticles
Adel, M., Zahmatkeshan, M., Akbarzadeh, A., Rabiee, N., Ahmadi, S., Keyhanvar, P., Rezayat, S. M., & Seifalian, A. M. (2022) · Biotechnology Reports · doi:10.1016/j.btre.2022.e00730 · Cited by 66
Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina
Berger, L., Elalfy, M., Martel, C., & Labrie, F. (2005) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.02.018 · Cited by 62
Breast cancer risk in the WHI study: The problem of obesity
Kühl, H. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.02.018 · Cited by 63
Hormone replacement therapy and cancer
Genazzani, A. R., Gadducci, A., & Gambacciani, M. (2001) · Climacteric · doi:10.1080/cmt.4.3.181.193 · Cited by 67
Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer
Lanari, C., & Molinolo, A. (2002) · Breast Cancer Research · doi:10.1186/bcr539 · Cited by 62
Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women
Lignieres, B. D., de Vathaire, F., Fournier, S., et al. (2002) · Climacteric · doi:10.1080/cmt.5.4.332.340 · Cited by 62
Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2
Cui, X., Lazard, Z. W., Zhang, P., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206803 · Cited by 61
Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors
Clark, N. C., Friel, A. M., Pru, C. A., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139240 · Cited by 60
Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future
Schwartz, E., & Holtorf, K. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.07.015 · Cited by 59
Sleep-Related Eating Disorder Induced by Risperidone
Lu, M., & Shen, W. W. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0220a · Cited by 60
Established Risk Factors Account for Most of the Racial Differences in Cardiovascular Disease Mortality
Henderson, S. O., Haiman, C. A., Wilkens, L. R., Kolonel, L. N., Wan, P. C., & Pike, M. C. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000377 · Cited by 58
Endometriosis as a model for inflammation–hormone interactions in ovarian and breast cancers
Ness, R. B., & Modugno, F. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.009 · Cited by 59
The Million Women Study: A Critique
Whitehead, M. I., & Farmer, R. D. T. (2004) · Endocrine · doi:10.1385/endo:24:3:187 · Cited by 58
Risk of breast cancer with progestins: critical assessment of current data
Santen, R. J. (2003) · Steroids · doi:10.1016/s0039-128x(03)00138-7 · Cited by 56
A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden)
Jernström, H., Bendahl, P., Lidfeldt, J., Nerbrand, C., Agardh, C., & Samsioe, G. (2003) · Cancer Causes & Control · doi:10.1023/a:1025635720208 · Cited by 57
Progestogen therapies: differences in clinical effects?
Wiegratz, I., & KUHL, H. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.06.006 · Cited by 57
Sex-steroid regulation of vascular endothelial growth factor in breast cancer
Hyder, S. M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00931 · Cited by 58
Effects of different types of hormone replacement therapy on mammographic density
Colacurci, N., Fornaro, F., FRANCISCIS, P. D., et al. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00232-8 · Cited by 56
Histologic changes in the breast with menopausal hormone therapy use
Harvey, J. A., Santen, R. J., Petroni, G. R., et al. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318054e29a · Cited by 55
Breast Cancer
Colditz, G. A., Baer, H. J., & M., T. R. (2006) · doi:10.1093/acprof:oso/9780195149616.003.0051 · Cited by 54
Symptoms and Treatment in Cancer Therapy-Induced Early Menopause
Boekhout, A. H., Beijnen, J. H., & Schellens, J. H. M. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-641 · Cited by 55
Progestin and G Protein-Coupled Receptor 30 Inhibit Mitogen-Activated Protein Kinase Activity in MCF-7 Breast Cancer Cells
Ahola, T. M., Alkio, N., Manninen, T., & Ylikomi, T. J. (2002) · Endocrinology · doi:10.1210/en.2002-220492 · Cited by 54
Does Menopausal Hormone Replacement Therapy Interact With Known Factors to Increase Risk of Breast Cancer?
Ursin, G., Tseng, C.-C., Paganini‐Hill, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.699 · Cited by 54
Self-citation
Breast response to menopausal hormone therapy—aspects on proliferation, apoptosis and mammographic density
Conner, P. (2007) · Annals of Medicine · doi:10.1080/07853890601039842 · Cited by 53
Breast cancer epidemiology, prevention, and early detection
Brewster, A. M., & Helzlsouer, K. J. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00002 · Cited by 53
Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality
Durna, E. M., Leader, L. R., Sjöblom, P., et al. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04835.x · Cited by 53
Integrating signals between cAMP and MAPK pathways in breast cancer
Castoria, G. (2007) · Frontiers in bioscience · doi:10.2741/2764 · Cited by 52
Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice
Liang, Y., Benakanakere, I., Besch-Williford, C. L., et al. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181d3dd0c · Cited by 52
Controversial issues in climacteric medicine II
Genazzani, A. R., Gadducci, A., & Gambacciani, M. (2001) · Maturitas · doi:10.1016/s0378-5122(01)00282-1 · Cited by 51
Menopausal hormone therapy in relation to breast cancer characteristics and prognosis: a cohort study
Rosenberg, L. U., Granath, F. N., Dickman, P. W., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2145 · Cited by 52
Progestins and breast cancer
Eden, J. (2003) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2003.201 · Cited by 52
Ovarian steroids and the human breast: Regulation of stem cells and cell proliferation
Clarke, R. B. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.06.002 · Cited by 52
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation
Salatino, M., Béguelin, W., Peters, M. G., Carnevale, R. P., Proietti, C. J., Galigniana, M. D., Vedoy, C. G., Schillaci, R., Charreau, E. H., Sogayar, M. C., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209757 · Cited by 50
The Relevance of the Women’s Health Initiative Results on Combined Hormone Replacement Therapy in Clinical Practice
Lemay, A. (2002) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30326-7 · Cited by 51
Age and Menopausal Effects of Hormonal Birth Control and Hormone Replacement Therapy in Relation to Breast Cancer Risk
Shantakumar, S., Terry, M. B., Paykin, A. B., Teitelbaum, S. L., Britton, J. A., Moorman, P. G., Kritchevsky, S. B., Neugut, A. I., & Gammon, M. D. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm006 · Cited by 50
Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure
Krul, I. M., Winden, A. W. J. O., Aleman, B. M. P., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.07.016 · Cited by 49
Hormone replacement therapy and cancer risk
Mahavni, V., & Sood, A. K. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200109000-00012 · Cited by 48
Val158Met Polymorphism in catechol-O-methyltransferase gene associated with risk factors for breast cancer.
Hong, C. C., Thompson, H. J., Jiang, C., Hammond, G. L., Tritchler, D., Yaffe, M. J., & Boyd, N. F. (2003) · PubMed · Cited by 49
Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy
Tannen, R. L., Weiner, M. G., Xie, D., et al. (2007) · Human Reproduction · doi:10.1093/humrep/dem031 · Cited by 48
Dual effects of isoflavonoids from Pueraria lobata roots on estrogenic activity and anti-proliferation of MCF-7 human breast carcinoma cells
Ahn, S.-Y., Jo, M. S., Lee, D. Y., et al. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.017 · Cited by 48
Ethnic differences in ovulatory function in nulliparous women
Haiman, C. A., Pike, M. C., Bernstein, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600098 · Cited by 48
Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy
Stahlberg, C. I., Pedersen, A. T., Andersen, Z. J., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601996 · Cited by 48
Breast cancer and sex steroids: Critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer
Gadducci, A., Biglia, N., Sismondi, P., & Genazzani, A. R. (2005) · Gynecological Endocrinology · doi:10.1080/09513590500128492 · Cited by 47
Risk of colorectal cancer after breast cancer.
Newschaffer, C., Topham, A., Herzberg, T., Weiner, S., & Weinberg, D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04197-0 · Cited by 46
The Functional Role of Notch Signaling in Triple-Negative Breast Cancer
Speiser, J. J., Erşahin, Ç. H., & Osipo, C. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00013-7 · Cited by 51
Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition
Mueck, A. O., Seeger, H., & Wallwiener, D. R. (2003) · Climacteric · doi:10.1080/cmt.6.3.221.227 · Cited by 47
The Risk of Breast, Endometrial and Ovarian Cancer in Users of Hormonal Preparations
Bernstein, L. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2006.pto_277.x · Cited by 47
Prediagnostic Use of Hormone Therapy and Mortality After Breast Cancer
Newcomb, P. A., Egan, K. M., Trentham‐Dietz, A., Titus-Ernstoff, L. T., Baron, J. A., Hampton, J. M., Stampfer, M. J., & Willett, W. C. (2008) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0610 · Cited by 46
Development and Characterization of a Progressive Series of Mammary Adenocarcinoma Cell Lines Derived from the C3(1)/SV40 Large T-antigen Transgenic Mouse Model
Holzer, R. G., MacDougall, C. A., Cortright, G., Atwood, K., Green, J. E., & Jorcyk, C. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1021175931177 · Cited by 46
Activation of estrogen receptor-β by a special extract of Rheum rhaponticum (ERr 731®), its aglycones and structurally related compounds
Wober, J., Möller, F. J., Richter, T., Unger, C., Weigt, C., Jandausch, A., Zierau, O., Rettenberger, R., Kaszkin-Bettag, M., & Vollmer, G. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.04.002 · Cited by 46
Human breast cell proliferation and its relationship to steroid receptor expression
Clarke, R. B. (2004) · Climacteric · doi:10.1080/13697130410001713751 · Cited by 46
Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys
Ethun, K. F., Wood, C. E., Register, T. C., Cline, J. M., Appt, S. E., & Clarkson, T. B. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318252e46d · Cited by 45
Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens
Hofvind, S. S. H., Møller, B., Thoresen, S., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21742 · Cited by 45
Progestin-mediated activation of MAPK and AKT in nuclear progesterone receptor negative breast epithelial cells: The role of membrane progesterone receptors
Salazar, M. G. S., Lerma-Ortiz, A., Hooks, G. M., Ashley, A. K., & Ashley, R. L. (2016) · Gene · doi:10.1016/j.gene.2016.06.044 · Cited by 45
Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer
Modugno, F., Kip, K. E., Cochrane, B. B., Kuller, L. H., Klug, T. L., Rohan, T. E., Chlebowski, R. T., Lasser, N. L., & Stefanick, M. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21487 · Cited by 45
Progestin inhibition of cell death in human breast cancer cell lines
Moore, M. R., Spence, J. B., Kiningham, K. K., et al. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2005.09.008 · Cited by 45
Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy
Schütz, F., Diel, I., Pueschel, M., et al. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.10.901 · Cited by 45
Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial
Antoine, C. (2004) · Human Reproduction · doi:10.1093/humrep/deh112 · Cited by 45
Progesterone receptors - animal models and cell signaling in breast cancer: Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics
Soyal, S. M., Ismail, P. M., Li, J., et al. (2002) · Breast Cancer Research · doi:10.1186/bcr451 · Cited by 45
Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model.
Haslam, S. Z., Osuch, J. R., Raafat, A. M., & Hofseth, L. J. (2002) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1015726608146 · Cited by 45
Use of Antidepressant Medications and the Possible Association with Breast Cancer Risk
Bahl, S., Cotterchio, M., & Kreiger, N. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000070782 · Cited by 44
Current comprehensive assessment and management of women at increased risk for breast cancer
Hollingsworth, A. B., Singletary, S. E., Morrow, M., Francescatti, D., O’Shaughnessy, J., Hartman, A., Haddad, B., Schnabel, F. R., & Vogel, V. G. (2004) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2003.12.025 · Cited by 44
From the ranks of mammary progesterone mediators, RANKL takes the spotlight
Fernandez‐Valdivia, R., & Lydon, J. P. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.030 · Cited by 43
Breast cancer: occurrence, risk factors and hormone metabolism
Sasco, A. J., Kaaks, R., & Little, R. E. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.4.546 · Cited by 42
Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM
McDonnell, D. P., Chang, C., & Norris, J. D. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03999.x · Cited by 43
MPA and postmenopausal coronary artery atherosclerosis revisited
Clarkson, T. B., & Appt, S. E. (2003) · Steroids · doi:10.1016/s0039-128x(03)00123-5 · Cited by 43
Hormone replacement therapy and risk of breast cancer: the role of progestins
Stahlberg, C. I., Pedersen, A. T., Lynge, E., et al. (2003) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1034/j.1600-0412.2003.00055.x · Cited by 43
Single‐center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti–tumor necrosis factor α therapy: Is there a need for more comprehensive screening procedures?
Nannini, C., Cantini, F., Niccoli, L., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24506 · Cited by 42
Stable mesoporous silica nanoparticles incorporated with MoS2 and AIE for targeted fluorescence imaging and photothermal therapy of cancer cells
Wang, J., Xu, M., Wang, K., et al. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.11.030 · Cited by 42
In vitro cytotoxic activity of six Syzygium leaf extracts as related to their phenolic profiles: An untargeted UHPLC-QTOF-MS approach
Rocchetti, G., Lucini, L., Ahmed, S. R., & Saber, F. R. (2019) · Food Research International · doi:10.1016/j.foodres.2019.108715 · Cited by 48
Osteoporosis and breast cancer
Fontanges, É., Fontana, A., & Delmas, P. D. (2003) · Joint Bone Spine · doi:10.1016/j.jbspin.2003.02.001 · Cited by 40
Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Sprague–Dawley Rats
Mafuvadze, B., Benakanakere, I., Lopez, F. R., et al. (2011) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0382 · Cited by 42
Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada
Kirsh, V. A., & Kreiger, N. (2002) · Cancer Causes & Control · doi:10.1023/a:1016330024268 · Cited by 42
Breast cancer and post-menopausal hormone therapy
Kenemans, P., & Bosman, A. (2003) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/s1521-690x(02)00084-2 · Cited by 42
Breast and Uterine Effects of Soy Isoflavones and Conjugated Equine Estrogens in Postmenopausal Female Monkeys
Wood, C. E., Register, T. C., Anthony, M. S., Kock, N. D., & Cline, J. M. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032067 · Cited by 42
Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategies
Clamp, A. R., Danson, S. J., & Clemons, M. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00875-6 · Cited by 42
Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling, J. R., Malone, K. E., Doody, D. R., Voigt, L. F., Bernstein, L., Marchbanks, P. A., Coates, R. J., Norman, S. A., Weiss, L. K., Ursin, G., et al. (2003) · PubMed · Cited by 42
Understanding Susceptibility to Breast Cancer: From Risk Factors to Prevention Strategies
García‐Sancha, N., Corchado‐Cobos, R., & Pérez‐Losada, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072993 · Cited by 55
Hormone replacement therapy and endometrial cancer.
Emons, G., Huschmand-Nia, A., Krauss, T., & Hinney, B. (1977) · PubMed · Cited by 41
Breast cancer prevention: present and future
Salih, A. K., & Fentiman, I. S. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0235 · Cited by 40
Progestin effects on cell proliferation pathways in the postmenopausal mammary gland
Wood, C. E., Branstetter, D. G., Jacob, A. P., Cline, J. M., Register, T. C., Rohrbach, K., Huang, L., Borgerink, H. M., & Dougall, W. C. (2013) · Breast Cancer Research · doi:10.1186/bcr3456 · Cited by 38
A novel mechanism: Erxian Decoction, a Chinese medicine formula, for relieving menopausal syndrome
Sze, S. C. W., Tong, Y., Zhang, Y.-B., et al. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.02.034 · Cited by 39
Therapy for Menopausal Symptoms During and After Treatment for Breast Cancer
Baber, R., Hickey, M., & Kwik, M. (2005) · Drug Safety · doi:10.2165/00002018-200528120-00004 · Cited by 37
A population-based cohort study of HRT use and breast cancer in southern Sweden
Olsson, H. L., Bladström, A., Ingvar, C., & Möller, T. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1899 · Cited by 37
Effect of Progesterone Receptor A Predominance on Breast Cancer Cell Migration into Bone Marrow Fibroblasts
McGowan, E. M., Saad, S., Bendall, L. J., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000014041.58977.80 · Cited by 38
Hormone Replacement Therapy: Real Concerns and False Alarms
Bluming, A. Z., & Tavris, C. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e31819e332a · Cited by 40
Risk of breast and ovarian cancer in women with strong family histories.
Srivastava, A., McKinnon, W. C., & Wood, M. E. (2001) · PubMed · Cited by 38
Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause?
Seeger, H., & Mueck, A. O. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.12.002 · Cited by 37
Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells
Carroll, C. E., Ellersieck, M. R., & Hyder, S. M. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31814fae5d · Cited by 37
Impedometric estrogen biosensor based on estrogen receptor alpha-immobilized gold electrode
Kim, B. K., Li, J., Im, J.-E., et al. (2012) · Journal of Electroanalytical Chemistry · doi:10.1016/j.jelechem.2012.02.022 · Cited by 37
Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas
Reed, S. D., Cushing‐Haugen, K. L., Daling, J. R., et al. (2004) · Menopause The Journal of The North American Menopause Society · doi:10.1097/01.gme.0000082297.18134.51 · Cited by 37
Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy
The MARIE-GENICA Consortium on Genetic Susceptibility for Menopausal Hormone Therapy Related Breast Cancer Risk (2009) · International Journal of Cancer · doi:10.1002/ijc.24892 · Cited by 37
Hormonal Replacement Therapy
Sitruk-Ware, R. L. (2002) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1020028510797 · Cited by 38
Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study
Lord, S. J., Mack, W. J., Berg, D. V. D., Pike, M. C., Ingles, S. A., Haiman, C. A., Wang, W., Parisky, Y. R., Hodis, H. N., & Ursin, G. (2005) · Breast Cancer Research · doi:10.1186/bcr999 · Cited by 37
Postmenopausal hormone therapy: from monkey glands to transdermal patches
Davis, S. R., Dinatale, I., Rivera‐Woll, L., & Davison, S. L. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.05847 · Cited by 36
Hormone-replacement therapy and breast cancer
Marsden, J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00732-5 · Cited by 38

Authors: Ross, R. K.
Affiliations: USC Norris Comprehensive Cancer Center (US)
Corresponding author: Ross, R. K.
Venue: Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2000-02-16
Volume: 92
Issue: 4
Pages: 328-332
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/92.4.328
OpenAlex: W3022279537
Cited by: 877
References: 0
Citations by year: 2026: 4 · 2025: 9 · 2024: 2 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 17 · 2019: 8 · 2018: 14 · 2017: 14 · 2016: 16 · 2015: 21 · 2014: 21 · 2013: 28 · 2012: 30
FWCI: 73.78
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (n01pc067010-004)
National Cancer Institute (CA 17054, P01CA017054, CA14089, P30CA014089, PC67010)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords: hormone replacement therapy, breast cancer risk, estrogen plus progestin, postmenopausal women, hormone-dependent breast cancer, breast cancer risk factors, duration of HRT use, Los Angeles
MeSH terms: Aged, Breast Neoplasms, California, Estrogens, Female, Humans, Middle Aged, Progestins, Risk, Risk Factors, Time Factors, Estrogen Replacement Therapy, Odds Ratio, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks